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Rituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, is an effective treatment for haematological
autoimmune diseases such as idiopathic thrombocytopenic purpura (ITP). A 72-year-old man was
diagnosed with idiopathic thrombocytopenic purpura (ITP). After receiving 4 cycles of rituximab in one
month complete response was achieved. However, three weeks after the last infusion he presented to the
haematology department with fever, productive cough and dyspnea and severe hypoxemia. HRCT of the
thorax revealed patchy areas of ground glass opacities throughout both lungs and small peripheral
consolidations were seen. Transbronchial biopsy showed interstitial thickening and type II pneumocyte
activation with interstitial pneumonia. Bronchoalveolar lavage showed increased eosinophils. The
patient was treated with three pulses of 1 gr iv methylprednisolone and then gradually switched to
15 mg of prednisolone for 3 months. The dyspnea and tachypnea gradually improved, in addition to
blood oxygenation and a follow up HRCT 3 months later showed a signiﬁcant resolution of lesions.
Severe lung toxicity like acute respiratory distress syndrome, cryptogenic organizing pneumonia,
pneumonitis, and interstitial lung disease are very rare, with most of the knowledge coming from case
reports. Rituximab-induced interstitial lung disease (R-ILD) is a rare complication. To the best of our
knowledge, 23 cases of R-ILD have been reported in the literature; 22 of them were treated with R-CHOP
for NHL and only one was receiving rituximab for ITP. We report the second case to develop this
complication for a non-malignant disorder.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Rituximab, a chimeric anti-CD20 IgG1monoclonal antibody, is an
effective treatment for haematological autoimmune diseases such
as idiopathic thrombocytopenic purpura (ITP) (Figs 1 and 2).1–3
Recently, it has become clear that B cells play a key role in both the
development and perpetuation of autoimmunity, suggesting that B-
cell depletion could be a valuable treatment approach for patients
with autoimmune diseases. Rituximab speciﬁcally depletes B cells
and is widely used today as second line treatment for ITP.1–3 The
most common side effects are infusion related and include fever,
chills, and rigours.4 Respiratory complications can include cough,
rhinitis, bronchospasm, dyspnea and sinusitis. Severe lung
toxicity like acute respiratory distress syndrome, cryptogenic
organizing pneumonia, pneumonitis, and interstitial lung diseasex: þ30 2810 542 650.
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reports.52. Case report
A 72-year-old man was diagnosed in march 2008 with idio-
pathic thrombocytopenic purpura. He initially received high dose
corticosteroids with no response. After receiving 4 cycles of rit-
uximab in one month (last one 5th May 2008) complete response
was achieved. Three weeks after the last infusion he presented to
the haematology department with fever, productive cough and
dyspnea and was transferred to our department for further eval-
uation. On physical evaluation he was tachypnoic and tachycardic.
Physical examination revealed bilateral crackles. He was hypox-
emic (PO2¼ 63 mmHg, FiO2 MV35%). Pulmonary function tests
revealed a mild restrictive pattern with severe reduction in
diffusion capacity (DLco¼ 37.2% pred.) (Table 1). Chest X-ray
showed a bilateral hazy reticulonodular pattern in the middle and
lower lung ﬁelds Empirical broad spectrum antibiotics were
Fig. 1. a, b Initial HRCT in the upper (a) and lower lung ﬁelds (b) respectively, shows a reticular pattern of lesions in the peripheral third of both lungs, irregular interfaces and
interlobular septa thickening, traction bronchiectasis and bronchiolectasis (arrows) and patchy areas of ground glass attenuation (curved arrows).
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later showed worsening of inﬁltrates and a HRCT of the thorax was
performed. Patchy areas of ground glass opacities throughout both
lungs and small peripheral consolidations were seen. A micro-
cystic, reticular pattern of lesions implying intralobular thickening
was observed in the peripheral third of both lung ﬁelds, more
extended in the lower ﬁelds. Furthermore, dilated, irregular
bronchi and bronchioles compatible with traction bronchectasis/
bronchiolectasis, irregular interfaces and interlobular septa
pointed to a ﬁbrotic process. Small bilateral pleural effusions were
also evident.
The rapid progress of interstitial inﬁltrates in a previously
normal lung as was shown on chest X-rays, and the elements of
a ﬁbrotic process revealed by HRCT, pointed to a ﬁbrotic process in
the spectrum of nonspeciﬁc interstitial pneumonia (NSIP), acute
interstitial pneumonia (AIP) on radiological grounds. A bronchos-
copy with bronchoalveolar lavage and transbrochial biopsy was
performed. Bacterial, viral, Pneumocystis carinii (PCP) and fungal
cultures were all negative. Transbronchial biopsy showed intersti-
tial thickening and type II pneumocyte activation with interstitial
pneumonia. Bronchoalveolar lavage showed increased eosinophils
(7%). The patient was treated with three pulses of 1 gr iv methyl-
prednisolone and then gradually switched to 15 mg of prednisolone
for 3 months. The dyspnea and tachypnea gradually improved, in
addition to blood oxygenation (PO2¼ 63 mmHg, FiO2¼ 21%) while
chest X-rays gradually improved. A follow up HRCT 3 months later
showed a signiﬁcant resolution of lesions. However, microcystic
lesions along with traction bronchiectasis, bronchiolectasis and
irregularly thickened interlobular septa remained in the peripheral
third of the lungs.Fig. 2. a, b Follow up HRT at the same levels, shows residual microcystic lesions in3. Discussion
Current treatment regimens for haematological autoimmune
diseases are relatively non-selective and are often associated with
considerable toxicity. Recent studies suggest that most patients
with immune thrombocytopenic purpura have a disease that is
generally well tolerated, with little morbidity. Splenectomy
remains the best ‘curative’ treatment for adults with chronic
disease (at least 6 months of follow up). Other treatments such as
anti-D, rituximab or dexamethasone may allow the decision of
splenectomy to be postponed, possibly indeﬁnitely, if haemostatic
platelet count is attained.1–3
Adverse pulmonary reactions to rituximab occur as reversible
events during the ﬁrst infusion in 38% of patients. In addition,
severe human antibody infusion reactions, generally occurring
during the ﬁrst 2 h of the ﬁrst infusion, can present with hypo-
tension or angioedema. Pulmonary involvement manifests in the
form of bronchospasm, hypoxia, inﬁltrates and even acute respi-
ratory distress syndrome. Late occurring pulmonary toxicities like
cryptogenic organizing pneumonia, pneumonitis, and interstitial
lung disease after the administration of rituximab have rarely been
reported.6
Rituximab induced interstitial lung disease (R-ILD) is a rare
complication. 23 cases of R-ILD were found in the literature; 22 of
them were treated with R-CHOP for NHL and only one was
receiving rituximab for ITP.8–10
The almost complete resolution of the HRCT ﬁndings in associ-
ation with clinical improvement and the eosinophilic reaction in
bronchoalveolar lavage ﬂuid suggest a drug reaction. The HRCT
ﬁndings are more consistent with an NSIP like reaction as AIP isthe peripheral and dorsal areas as well as traction bronchiolectasis (b, arrow).
Table 1
Pulmonary Function Tests (PFTs) before and after treatment.
Values Before treatment 3 months after treatment
FEV 1 72.3% pred 96.3% pred
FVC 65.4% pred 86.5% pred
FEV 1/FVC 84.87% pred 85.54% pred
MMEF 75/25 80.1% pred 79.5% pred
TLCOc 37.2% pred 64.1% pred
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pathologic proﬁle of diffuse alveolar damage.
The pathogenesis of R-ILD is largely unknown. The possible
pathogenetic mechanisms include the role of complement activa-
tion, cytokines, cytotoxic T lymphocytes (CTL) and CD 20 positive
T-cells. CTL activation may produce vascular and alveolar damage.
Disturbed cellular cytotoxicity can also result from the interaction
of rituximab with CD 20þ T-cells or by crossreactivity between
lung and tumoral antigens with possible generation of a self reac-
tive clone. Complement activation and cytokine secretion seems to
be the causative factors in side effects associated with infusion
reactions. In particular, TNF-a has been postulated as the main
component in the pathogenesis of ILD because of its proin-
ﬂammatory effects by inducing chemokines, inﬂammatory medi-
ators, and angiogenic factors.7,8
R-ILD can occur in adult patients who have received rituximab
therapy for months. Presenting symptoms include dyspnea, fever,
pleuritic pain and cough. Evaluation should include pulse oxymetry
and arterial blood gases, a HRCT of the chest and PFTs to determine
the pattern of pulmonary disease present. Bronchoscopy with
bronchoalveolar lavage should be done to rule out an infectious
etiology and biopsy can demonstrate interstitial ﬁbrosis.
The emergence of pulmonary inﬁltrates in patients treated with
rituximab remains a difﬁcult diagnostic problem. Many differential
diagnoses need to be considered, including disease progression,
infection, cardiogenic edema, radiation pneumonitis, pulmonary
hemorrhage, and allergies. One of the major clinical challenges in
these patients is ruling out opportunistic infection. The infectious
etiologies of diffuse interstitial inﬁltrates in the lungs are multiple.9They include any Gram-negative or Gram-positive agents, fungi
(Aspergillus, Candida), parasites (P. carinii, Toxoplasma gondii), or
viruses (Herpes simplex, Varicella zoster, Cytomegalovirus).9
Therapy must include corticosteroids, immediate discontinua-
tion of rituximab, and any other clinically necessary measures such
as mechanical ventilation. Of the 23 patients treated as mentioned
above, 15 lived and 8 of them died. These data suggest that R-ILD is
a rare but fatal pulmonary toxicity and the physicians must main-
tain a high index of suspicion to recognize this complication early.
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